Company news
Sanbio Co., Ltd. (TSE:4592) news
Sanbio Co., Ltd. news releases on 6ix. Latest, Sep 17, 2026: Presentation for Financial Results for the 2nd Quarter of the Fiscal Year Ending January 31, 2027
Press releases & updates
Presentation for Financial Results for the 2nd Quarter of the Fiscal Year Ending January 31, 2027
September 17, 2026
[Delayed] Consolidated Financial Results for the Six Months Ended July 31, 2026 [Japanese GAAP]
September 15, 2026
Notice Concerning Recording of Non-operating Income,Non-operating Expenses and Deferred Income Taxes
September 14, 2026
[Delayed] Notice Regarding Integration of AKUUGO(R) Manufacturing Operations in Japan Following Closure of Minaris’ U.S. Facility
September 7, 2026
[Delayed]Notice Concerning Recording of Non-operating Income and Deferred Income Taxes
June 16, 2026
Consolidated Financial Results for the Three Months Ended April 30, 2026[Japanese GAAP]
June 15, 2026
SanBio Obtains Marketing Approval for AKUUGO Suspension for Intracranial Implantation as a Therapeutic Agent for Improving Chronic Motor Paralysis from Traumatic Brain Injury
August 1, 2024
SanBio Obtains Marketing Approval for “AKUUGO® Suspension for Intracranial Implantation” (INN: Vandefitemcel) as a Therapeutic Agent for Improving Chronic Motor Paralysis From Traumatic Brain Injury (TBI)
July 31, 2024
SanBio : Announcement on Granting Stock Options (Share Acquisition Rights)
August 16, 2022
SanBio : Notice regarding appointment of new corporate officers
August 1, 2022
SanBio : Update on Status of Manufacturing and Marketing Approval for SB623 Chronic Traumatic Brain Injury (TBI) Program in Japan
July 22, 2022
SanBio : Keizo Nakada to Join SanBio as Corporate Officer and Head of Production
July 1, 2022
SanBio : Recording of Non-operating Income (Foreign Exchange Gains), Deferred Income Taxes, and Short-Term Loans Payable
June 15, 2022
SanBio : Consolidated Financial Results for the Three Months Ended April 30, 2022
June 14, 2022
SanBio : Andrew Liu to Join SanBio as Chief Strategy Officer
June 1, 2022
SanBio : SB623 Demonstrated Sustained Improvement in Motor Impairment up to 48 Weeks and Associated with Improvement
April 5, 2022
SB623 Demonstrated Sustained Improvement in Motor Impairment up to 48 Weeks and Associated with Improvement in Function and Activities of Daily Living in Patients with Chronic Traumatic Brain Injury
April 5, 2022
SanBio : ［Delayed］Recording of Non-Operating Expenses (Financing Expenses)
March 23, 2022
SanBio : Partial Amendment to the Articles of Incorporation, Reduction in Amounts of Stated Capital and Capital Reserves and Appropriation of Capital Surplus
March 11, 2022
SanBio : Announcement on Issuance Plans of Stock Options (Share Acquisition Rights)
March 11, 2022
SanBio : Presentation for Financial Results for the Fiscal Year Ending Jan.31, 2022
March 11, 2022
SanBio : Consolidated Financial Results for the Fiscal Year Ended January 31, 2022
March 11, 2022
SanBio: Notice Regarding Completion of Approval Filing for Japan SB623 Chronic TBI Program
March 7, 2022
SanBio : Notice regarding completion of approval filing for Japan SB623 chronic TBI program
March 7, 2022
SanBio : Consolidated Financial Results for the Nine Months Ended October 31, 2021
December 16, 2021
SanBio : Notice on the recording of other comprehensive income, non-operating income, and non-operating expenses
December 15, 2021
SanBio : Notice on Conclusion of Committed Credit Line Agreement with Resona Bank Ltd.
December 15, 2021
SanBio Joins the Newly Formed National TBI Registry Coalition (NTRC) as a Founding Member Organization
December 15, 2021
SanBio : Business Partnership for Development and Commercialization of Regenerative Medicine MSC2
November 16, 2021
Business Partnership for Development and Commercialization of Medical Device Implant Utilizing MSC2 for the Regeneration of Esophageal Tissue in Humans
November 16, 2021
SanBio Announces Publication Comparing Outcome Measures for Persons With Chronic Traumatic Brain Injury in Expert Review of Neurotherapeutics
November 1, 2021